
Tim F Greten

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2780793/publications.pdf Version: 2024-02-01



TIM F COFTEN

#	Article	IF	CITATIONS
1	Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine, 2008, 359, 378-390.	13.9	12,004
2	EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 2012, 56, 908-943.	1.8	5,214
3	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017, 357, 409-413.	6.0	4,945
4	IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer. Cell, 2004, 118, 285-296.	13.5	2,277
5	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nature Communications, 2016, 7, 12150.	5.8	2,076
6	Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study. CardioVascular and Interventional Radiology, 2010, 33, 41-52.	0.9	1,329
7	Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells. Science, 2018, 360, .	6.0	931
8	A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells. Gastroenterology, 2008, 135, 234-243.	0.6	722
9	Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2017, 66, 545-551.	1.8	624
10	Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma. Cancer Research, 2005, 65, 2457-2464.	0.4	561
11	NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature, 2016, 531, 253-257.	13.7	552
12	Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology, 2009, 50, 799-807.	3.6	532
13	Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2012, 18, 2290-2300.	3.2	503
14	Safety and Survival With GVAX Pancreas Prime and <i>Listeria Monocytogenes</i> –Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2015, 33, 1325-1333.	0.8	490
15	Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer. Cancer Cell, 2019, 36, 418-430.e6.	7.7	433
16	Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 293-313.	8.2	428
17	EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. European Journal of Cancer, 2012, 48, 599-641.	1.3	406
18	Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial. Journal of Clinical Oncology, 2014, 32, 2423-2429.	0.8	397

#	Article	IF	CITATIONS
19	Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression. Cancer Cell, 2016, 30, 533-547.	7.7	397
20	Myeloid derived suppressor cells in human diseases. International Immunopharmacology, 2011, 11, 802-807.	1.7	374
21	Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncology, The, 2014, 15, 819-828.	5.1	345
22	The yin and yang of evasion and immune activation in HCC. Journal of Hepatology, 2015, 62, 1420-1429.	1.8	274
23	Myeloid-Derived Suppressor Cells in Inflammatory Bowel Disease: A New Immunoregulatory Pathway. Gastroenterology, 2008, 135, 871-881.e5.	0.6	262
24	Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer, 2016, 122, 1757-1765.	2.0	245
25	Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8+ T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 7568-7573.	3.3	241
26	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology, 2021, 73, 158-191.	3.6	235
27	Singleâ€cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. Hepatology, 2018, 68, 127-140.	3.6	231
28	Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. Hepatology, 2014, 60, 1776-1782.	3.6	210
29	Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Annals of Oncology, 2009, 20, 1667-1673.	0.6	206
30	Gut microbiome in HCC – Mechanisms, diagnosis and therapy. Journal of Hepatology, 2020, 72, 230-238.	1.8	206
31	Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood, 2011, 117, 6532-6541.	0.6	205
32	Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune responsein vivo. International Journal of Cancer, 2003, 103, 205-211.	2.3	195
33	Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. Gastroenterology, 2019, 156, 510-524.	0.6	179
34	Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. British Journal of Cancer, 2005, 92, 1862-1868.	2.9	176
35	S100A9 a new marker for monocytic human myeloidâ€derived suppressor cells. Immunology, 2012, 136, 176-183.	2.0	176
36	A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer, 2010, 10, 209.	1.1	174

#	Article	IF	CITATIONS
37	Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cellular and Molecular Immunology, 2021, 18, 112-127.	4.8	159
38	Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 536-554.	8.2	158
39	Stat3 and NF-κB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology, 2002, 123, 2052-2063.	0.6	155
40	Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut, 2015, 64, 842-848.	6.1	155
41	Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 1007-1013.	1.8	154
42	Altered expression of the Ca2+-binding protein S100A1 in human cardiomyopathy. Biochimica Et Biophysica Acta - Molecular Cell Research, 1996, 1313, 253-257.	1.9	149
43	Combined locoregional-immunotherapy for liver cancer. Journal of Hepatology, 2019, 70, 999-1007.	1.8	146
44	Cancer Vaccines. Journal of Clinical Oncology, 1999, 17, 1047-1047.	0.8	139
45	Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Journal of Hepatology, 2021, 75, 1397-1408.	1.8	133
46	Troponin T: A diagnostic marker for myocardial infarction and minor cardiac cell damage. European Heart Journal, 1996, 17, 3-8.	1.0	132
47	Spontaneous Tumor-Specific Humoral and Cellular Immune Responses to NY-ESO-1 in Hepatocellular Carcinoma. Clinical Cancer Research, 2004, 10, 4332-4341.	3.2	132
48	Cytotoxic CD4+ T cells in viral hepatitis. Journal of Viral Hepatitis, 2006, 13, 505-514.	1.0	130
49	Targets for immunotherapy of liver cancer. Journal of Hepatology, 2018, 68, 157-166.	1.8	129
50	Increased Activated Human T Cell Lymphotropic Virus Type I (HTLVâ€I) Tax11â€19–Specific Memory and Effector CD8+Cells in Patients with HTLVâ€I–Associated Myelopathy/Tropical Spastic Paraparesis: Correlation with HTLVâ€I Provirus Load. Journal of Infectious Diseases, 2001, 183, 197-205.	1.9	128
51	Low-dose Cyclophosphamide Treatment Impairs Regulatory T Cells and Unmasks AFP-specific CD4+ T-cell Responses in Patients With Advanced HCC. Journal of Immunotherapy, 2010, 33, 211-218.	1.2	122
52	Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. Hepatology, 2015, 62, 481-495.	3.6	121
53	Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Annals of Oncology, 2013, 24, 1972-1979.	0.6	120
54	Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. Cancer Discovery, 2021, 11, 1248-1267.	7.7	117

#	Article	IF	CITATIONS
55	Complement 5a Receptor Inhibition Improves Renal Allograft Survival. Journal of the American Society of Nephrology: JASN, 2008, 19, 2302-2312.	3.0	112
56	Increase in frequency of myeloidâ€derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology, 2009, 128, 141-149.	2.0	111
57	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. Journal of Hepatology, 2012, 56, 1080-1088.	1.8	109
58	Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the â€~Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut, 2013, 62, 751-759.	6.1	105
59	Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. Journal of Immunology, 1999, 162, 1765-71.	0.4	105
60	Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy. Hepatology, 2019, 70, 1437-1442.	3.6	104
61	Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. Journal of Hepatology, 2019, 70, 449-457.	1.8	102
62	CD49d Is a New Marker for Distinct Myeloid-Derived Suppressor Cell Subpopulations in Mice. Journal of Immunology, 2010, 185, 203-210.	0.4	101
63	Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2006, 12, 3275.	1.4	99
64	The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 599-608.	2.0	97
65	Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology, 2020, 158, 2250-2265.e20.	0.6	97
66	Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. Nature Communications, 2021, 12, 1455.	5.8	96
67	Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scandinavian Journal of Gastroenterology, 2011, 46, 1092-1098.	0.6	94
68	Fibrolamellar hepatocellular carcinoma in the USA, 2000–2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database. United European Gastroenterology Journal, 2013, 1, 351-357.	1.6	93
69	Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2018, 67, 1305-1315.	2.0	93
70	Mitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis. Cell, 2018, 174, 88-101.e16.	13.5	93
71	Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development. Cell Death and Disease, 2018, 9, 620.	2.7	90
72	Enhanced Tumor Protection by Granulocyte-Macrophage Colony-Stimulating Factor Expression at the Site of an Allogeneic Vaccine. Human Gene Therapy, 1998, 9, 835-843.	1.4	89

#	Article	IF	CITATIONS
73	Hepatocellular Carcinoma from an Immunologic Perspective. Clinical Cancer Research, 2013, 19, 6678-6685.	3.2	89
74	Hepatocellular Carcinoma Survival by Etiology: A SEERâ€Medicare Database Analysis. Hepatology Communications, 2020, 4, 1541-1551.	2.0	87
75	EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. British Journal of Cancer, 2013, 108, 469-476.	2.9	84
76	Endogenous Adenosine Curtails Lipopolysaccharide‣timulated Tumour Necrosis Factor Synthesis. Scandinavian Journal of Immunology, 1997, 45, 132-139.	1.3	81
77	A Phase I Clinical Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma. The Johns Hopkins Oncology Center, Baltimore, Maryland. Human Gene Therapy, 1998, 9, 1951-1971.	1.4	78
78	Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology, 2014, 60, 1637-1644.	3.6	78
79	Tremelimumab in Combination With Microwave Ablation in Patients With RefractoryÂBiliary Tract Cancer. Hepatology, 2019, 69, 2048-2060.	3.6	77
80	CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. Journal of Hepatology, 2021, 74, 1145-1154.	1.8	76
81	A research agenda for curing chronic hepatitis B virus infection. Hepatology, 2018, 67, 1127-1131.	3.6	70
82	Immunotherapy of hepatocellular carcinoma. Journal of Hepatology, 2006, 45, 868-878.	1.8	69
83	Molecular therapy for the treatment of hepatocellular carcinoma. British Journal of Cancer, 2009, 100, 19-23.	2.9	69
84	Tumor regulation of the tissue environment in the liver. , 2017, 173, 47-57.		68
85	Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. Clinical Cancer Research, 2017, 23, 4633-4641.	3.2	68
86	The Diagnosis and Treatment of Hepatocellular Carcinoma. Deutsches Ärzteblatt International, 2014, 111, 101-6.	0.6	66
87	Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice. Journal of Leukocyte Biology, 2012, 92, 1199-1206.	1.5	61
88	Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000–10. Gut, 2013, 62, 1667-1668.	6.1	61
89	Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2010, 22, 391-398.	0.8	60
90	Immune Suppression: The Hallmark of Myeloid Derived Suppressor Cells. Immunological Investigations, 2012, 41, 581-594.	1.0	60

#	Article	IF	CITATIONS
91	Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. Journal of Hepatology, 2021, 74, 700-715.	1.8	60
92	Hepatocellular Carcinoma — Origins and Outcomes. New England Journal of Medicine, 2021, 385, 280-282.	13.9	60
93	The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma. Gut, 2022, 71, 1161-1175.	6.1	60
94	Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. Cancer Immunology, Immunotherapy, 2013, 62, 299-307.	2.0	58
95	A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results. Journal of Clinical Oncology, 2007, 25, 4598-4598.	0.8	58
96	<scp>IFN</scp> â€Î³ regulates survival and function of tumorâ€induced <scp>CD</scp> 11b ⁺ <scp>G</scp> râ€1 ^{high} myeloid derived suppressor cells by modulating the antiâ€apoptotic molecule <scp>B</scp> cl2a1. European Journal of Immunology, 2014, 44, 2457-2467.	1.6	57
97	Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. Journal of Hepatology, 2022, 77, 748-760.	1.8	57
98	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. , 2017, 5, 93.		56
99	Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecanâ€refractory colorectal cancer. International Journal of Cancer, 2016, 139, 1648-1657.	2.3	55
100	Immunotherapy of HCC. Reviews on Recent Clinical Trials, 2008, 3, 31-39.	0.4	54
101	Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2020, 26, 2318-2326.	3.2	54
102	Immunological off-target effects of standard treatments in gastrointestinal cancers. Annals of Oncology, 2014, 25, 24-32.	0.6	51
103	Programmed death-1 blockade in mismatch repair deficient colorectal cancer Journal of Clinical Oncology, 2016, 34, 103-103.	0.8	50
104	Human CCR4+CCR6+Th17 Cells Suppress Autologous CD8+ T Cell Responses. Journal of Immunology, 2012, 188, 6055-6062.	0.4	48
105	Steatohepatitis Impairs T-cell–Directed Immunotherapies Against Liver Tumors in Mice. Gastroenterology, 2021, 160, 331-345.e6.	0.6	46
106	Necrotic Tumor Cell Death In Vivo Impairs Tumor-Specific Immune Responses. Journal of Immunology, 2007, 178, 1573-1580.	0.4	44
107	Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage. Cancer Immunology Research, 2015, 3, 557-566.	1.6	44
108	Pancreatic Squamous Cell Carcinoma. Pancreas, 2016, 45, 1432-1437.	0.5	43

#	Article	IF	CITATIONS
109	Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma. Digestion, 2017, 96, 1-4.	1.2	43
110	Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes. FEBS Journal, 2018, 285, 752-762.	2.2	43
111	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
112	Peptide–β2-microglobulin–MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC–Ig complexes. Journal of Immunological Methods, 2002, 271, 125-135.	0.6	42
113	Engineered Antiâ€GPC3 Immunotoxin, HN3â€ABDâ€₹20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention. Hepatology, 2020, 71, 1696-1711.	3.6	42
114	Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC) Journal of Clinical Oncology, 2019, 37, 336-336.	0.8	41
115	Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. Hepatobiliary and Pancreatic Diseases International, 2007, 6, 259-66.	0.6	41
116	Genetically Induced Pancreatic Adenocarcinoma Is Highly Immunogenic and Causes Spontaneous Tumor-Specific Immune Responses. Cancer Research, 2006, 66, 508-516.	0.4	40
117	A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Investigational New Drugs, 2016, 34, 168-175.	1.2	40
118	Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients. Clinical Cancer Research, 2018, 24, 2859-2872.	3.2	40
119	PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers Journal of Clinical Oncology, 2016, 34, 195-195.	0.8	39
120	Immune Responses in Hepatocellular Carcinoma. Digestive Diseases, 2010, 28, 150-154.	0.8	38
121	Immunogenicity of necrotic cell death. Cellular and Molecular Life Sciences, 2015, 72, 273-283.	2.4	38
122	Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: A randomised trial. European Journal of Surgical Oncology, 2006, 32, 201-207.	0.5	37
123	Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. European Journal of Clinical Investigation, 2007, 37, 54-64.	1.7	36
124	A phase II study of TRC105Âin patients with hepatocellular carcinoma who have progressed on sorafenib. United European Gastroenterology Journal, 2015, 3, 453-461.	1.6	36
125	Participation in screening colonoscopy in first-degree relatives from patients with colorectal cancer. Annals of Oncology, 2007, 18, 1518-1522.	0.6	34
126	Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication. Aids, 1995, 9, 1137-1144.	1.0	33

#	Article	IF	CITATIONS
127	Primary sterile necrotic cells fail to cross-prime CD8 ⁺ T cells. OncoImmunology, 2012, 1, 1017-1026.	2.1	33
128	Transplant Oncology in Primary and Metastatic Liver Tumors. Annals of Surgery, 2021, 273, 483-493.	2.1	33
129	Suppression of tumor necrosis factor-α production by interleukin-10 is enhanced by cAMP-elevating agents. European Journal of Pharmacology, 1997, 321, 231-239.	1.7	32
130	Lipopolysaccharide-Mediated Mast Cell Activation Induces IFN-Î ³ Secretion by NK Cells. Journal of Immunology, 2010, 185, 119-125.	0.4	32
131	Hepatic myeloid-derived suppressor cells in cancer. Cancer Immunology, Immunotherapy, 2015, 64, 931-940.	2.0	32
132	The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-1± and nitric oxide. International Journal of Immunopharmacology, 1995, 17, 605-610.	1.1	31
133	Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1779-1786.	1.4	31
134	Cellular Immune Suppressor Mechanisms in Patients with Hepatocellular Carcinoma. Digestive Diseases, 2012, 30, 477-482.	0.8	31
135	A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2019, 18, e349-e360.	1.0	31
136	A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial. Journal of Clinical Oncology, 2009, 27, 4520-4520.	0.8	31
137	Nitric oxide downregulates tumour necrosis factor mRNA in RAW 264.7 cells. Research in Immunology, 1998, 149, 139-150.	0.9	30
138	Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer. Molecular Oncology, 2008, 2, 349-355.	2.1	30
139	pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC Cancer, 2014, 14, 624.	1.1	29
140	miR-130a and miR-145 reprogram Gr-1+CD11b+ myeloid cells and inhibit tumor metastasis through improved host immunity. Nature Communications, 2018, 9, 2611.	5.8	29
141	Activating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor Response. Cancer Immunology Research, 2021, 9, 1024-1034.	1.6	29
142	Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the †Arbeitsgemeinschaft Internistische Onkologie'. Anti-Cancer Drugs, 2010, 21, 94-100.	0.7	28
143	MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target. Cellular Immunology, 2021, 361, 104295.	1.4	28
144	Peptidases released by necrotic cells control CD8+ T cell cross-priming. Journal of Clinical Investigation, 2013, 123, 4755-4768.	3.9	28

#	Article	IF	CITATIONS
145	Graves' disease and sarcoidosis in a patient with minimal-change glomerulonephritis. Nephrology Dialysis Transplantation, 1996, 11, 860-862.	0.4	27
146	Personalized Oncology in Interventional Radiology. Journal of Vascular and Interventional Radiology, 2013, 24, 1083-1092.	0.2	27
147	Regorafenib as second-line therapy in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 141-142.	8.2	26
148	The case for immuneâ€based approaches in biliary tract carcinoma. Hepatology, 2016, 64, 1785-1791.	3.6	25
149	Maintenance of Peritoneal B-1a Lymphocytes in the Absence of the Spleen. Journal of Immunology, 2004, 173, 197-204.	0.4	24
150	Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology, 2013, 57, 1068-1077.	3.6	24
151	Immunotherapy: Current Status and Future Perspectives. Digestive Diseases and Sciences, 2019, 64, 1030-1040.	1.1	24
152	Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology Journal of Clinical Oncology, 2016, 34, 3003-3003.	0.8	24
153	Generation of activated and antigen-specific T cells with cytotoxic activity after co-culture with dendritic cells. Cancer Immunology, Immunotherapy, 2002, 51, 25-32.	2.0	23
154	A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. Oncologist, 2022, 27, e273-e285.	1.9	22
155	The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis. Trends in Cancer, 2022, 8, 583-597.	3.8	22
156	Immune based therapies in cancer. Histology and Histopathology, 2007, 22, 687-96.	0.5	22
157	Developing better treatments in hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2010, 4, 551-560.	1.4	21
158	Hepatocellular carcinoma occurring after successful treatment of childhood cancer with high dose chemotherapy and radiation. Gut, 2005, 54, 732-732.	6.1	20
159	Impaired TRAILâ€dependent cytotoxicity of CD1câ€positive dendritic cells in chronic hepatitis C virus infection. Journal of Viral Hepatitis, 2008, 15, 200-211.	1.0	20
160	Systematic evaluation of immune regulation and modulation. , 2017, 5, 21.		20
161	A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results Journal of Clinical Oncology, 2014, 32, 177-177.	0.8	20
162	Fulminant Hepatic Failure due to Chemotherapy-Induced Hepatitis B Reactivation: Role of Rituximab. Zeitschrift Fur Gastroenterologie, 2010, 48, 258-263.	0.2	19

#	Article	IF	CITATIONS
163	Immunosuppressive cell death in cancer. Nature Reviews Immunology, 2017, 17, 401-401.	10.6	19
164	A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer Journal of Clinical Oncology, 2016, 34, 560-560.	0.8	19
165	Tumor Induced Hepatic Myeloid Derived Suppressor Cells Can Cause Moderate Liver Damage. PLoS ONE, 2014, 9, e112717.	1.1	19
166	Immunotherapy of hepatocellular carcinoma. Expert Opinion on Biological Therapy, 2002, 2, 123-133.	1.4	18
167	Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization. International Journal of Biological Sciences, 2019, 15, 2654-2663.	2.6	18
168	Immunotherapy of hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2010, 4, 345-353.	1.4	17
169	Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells. Cellular Oncology, 2008, 30, 463-71.	1.9	17
170	Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-α synthesis. European Journal of Pharmacology, 1996, 299, 229-233.	1.7	16
171	Combination of Conservative and Interventional Therapy Strategies for Intra- and Extrahepatic Cholangiocellular Carcinoma: A Retrospective Survival Analysis. Gastroenterology Research and Practice, 2012, 2012, 1-8.	0.7	16
172	An Algorithm for Evaluating Human Cytotoxic T Lymphocyte Responses to Candidate AIDS Vaccines. AIDS Research and Human Retroviruses, 1999, 15, 1021-1034.	0.5	15
173	Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma. Immunology, 2009, 128, 134-140.	2.0	15
174	Radiofrequency ablation for the treatment of HCC – Maybe much more than simple tumor destruction?. Journal of Hepatology, 2010, 53, 775-776.	1.8	15
175	Cellular senescence associated immune responses in liver cancer. Hepatic Oncology, 2017, 4, 123-127.	4.2	15
176	Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1166-1178.	2.3	15
177	A pilot study of tremelimumab – a monoclonal antibody against CTLA-4 – in combination with either trans catheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2015, 33, 4081-4081.	0.8	15
178	Tumor-associated gene expression in disseminated tumor cells correlates with disease progression and tumor stage in colorectal cancer. Anticancer Research, 2007, 27, 1823-32.	0.5	15
179	Monitoring Antigen-Specific T Cells Using MHC-Ig Dimers. , 2001, Chapter 17, Unit 17.2.		14
180	Establishment of Orthotopic Liver Tumors by Surgical Intrahepatic Tumor Injection in Mice with Underlying Non-Alcoholic Fatty Liver Disease. Methods and Protocols, 2018, 1, 21.	0.9	14

#	Article	IF	CITATIONS
181	Gender disparity in HCC: Is it the fat and not the sex?. Journal of Experimental Medicine, 2019, 216, 1014-1015.	4.2	14
182	Microbiome genomics for cancer prediction. Nature Cancer, 2020, 1, 379-381.	5.7	14
183	Human Th17 cells in patients with cancer. Oncolmmunology, 2012, 1, 1438-1439.	2.1	13
184	Myeloid-derived suppressor cells in pancreatic cancer: more than a hidden barrier for antitumour immunity?. Gut, 2014, 63, 1690-1691.	6.1	12
185	FoxC1: Novel Regulator of Inflammation-Induced Metastasis in Hepatocellular Carcinoma. Gastroenterology, 2015, 149, 861-863.	0.6	12
186	Editorial: "Invisible―MDSC in tumor-bearing individuals after antibody depletion: fact or fiction?. Journal of Leukocyte Biology, 2016, 99, 794-794.	1.5	12
187	NAFLD indirectly impairs antigen-specific CD8+ TÂcell immunity against liver cancer in mice. IScience, 2022, 25, 103847.	1.9	12
188	Peptide-?2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells. Immunology, 2007, 122, 90-97.	2.0	11
189	The effects of platelet accumulation in fatty liver disease. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 393-394.	8.2	11
190	Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models. IScience, 2021, 24, 101990.	1.9	11
191	Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: Final analysis of a randomized phase II trial (BINGO) Journal of Clinical Oncology, 2012, 30, 4032-4032.	0.8	11
192	Development and Use of Multimeric Major Histocompatibility Complex Molecules. Vaccine Journal, 2002, 9, 216-220.	3.2	10
193	Tumorâ€induced CD11b ⁺ Grâ€l ⁺ myeloidâ€derived suppressor cells exacerbate immuneâ€mediated hepatitis in mice in a CD40â€dependent manner. European Journal of Immunology, 2015, 45, 1148-1158.	1.6	10
194	Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. Hepatic Oncology, 2015, 2, 39-50.	4.2	10
195	Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481880808.	1.4	10
196	Hepatocellular carcinoma (HCC) survival by etiology: A SEER-Medicare database analysis Journal of Clinical Oncology, 2019, 37, 201-201.	0.8	9
197	Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 507-512.	1.8	8
198	A pilot study of immune checkpoint inhibition in combination with radiation therapy in patients with metastatic pancreatic cancer Journal of Clinical Oncology, 2017, 35, e15786-e15786.	0.8	8

#	Article	IF	CITATIONS
199	A phase I/II study of pexa-vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer: Safety report Journal of Clinical Oncology, 2019, 37, 646-646.	0.8	8
200	MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. Cell Reports Methods, 2022, 2, 100136.	1.4	8
201	Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104. Acta Oncológica, 2015, 54, 993-1000.	0.8	7
202	Treating Hepatobiliary Cancer: The Immunologic Approach. Digestive Diseases, 2017, 35, 390-396.	0.8	7
203	CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC. Gut, 2018, 67, 783-784.	6.1	7
204	Tremelimumab: A monoclonal antibody against CTLA-4—In combination with subtotal ablation (trans) Tj ETQq(patients with hepatocellular carcinoma (HCC) and biliary tract carcinoma (BTC) Journal of Clinical Oncology, 2016, 34, 4073-4073.	0 0 0 rgBT 0.8	/Overlock 10 7
205	Bleeding events and eligibility requirements in studies evaluating an antiangiogenic agent in hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2011, 29, 310-310.	0.8	7
206	Molecular therapy of pancreatic cancer. Minerva Endocrinologica, 2010, 35, 27-33.	1.7	7
207	Specific immunotherapy in hepatocellular cancer: A systematic review. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 339-351.	1.4	6
208	Factitious hypertensive crisis (Munchhausen syndrome). Nephrology Dialysis Transplantation, 1996, 11, 893-894.	0.4	5
209	Mycosis Fungoides With Involvement of the Larynx After Liver Transplantation in an Adult. American Journal of Gastroenterology, 2010, 105, 238-240.	0.2	5
210	A pilot study of tremelimumab, a monoclonal antibody against CTLA-4, in combination with either transcatheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2014, 32, e15133-e15133.	0.8	5
211	Locally Advanced Cancer of the Esophagus, Current Treatment Strategies, and Future Directions. Frontiers in Oncology, 2012, 2, 52.	1.3	4
212	Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Stu. International Journal of Cancer, 2013, 132, 1718-1718.	2.3	4
213	Response to fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: better 5-year survival or artefactual result of research methodology?. Gut, 2014, 63, 1524.1-1524.	6.1	4
214	Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization. Journal of Vascular and Interventional Radiology, 2019, 30, 19-22.	0.2	4
215	Abstract 1728: Nonalcoholic steatohepatitis (NASH) impairs treatment of intrahepatic metastases with CD4+ T cell dependent RNA vaccine. Cancer Research, 2018, 78, 1728-1728.	0.4	4
216	Checkpoint Inhibitors Modulate Plasticity of Innate Lymphoid Cells in Peripheral Blood of Patients With Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	4

#	Article	IF	CITATIONS
217	Commensal bacteria (ab)use CD8 ⁺ T cells to induce insulin resistance. Science Immunology, 2017, 2, .	5.6	3
218	Does CSF1R Blockade Turn into Friendly Fire?. Cancer Cell, 2017, 32, 546-547.	7.7	3
219	Development of shellfish allergy after exposure to dual immune checkpoint blockade. Hepatic Oncology, 2018, 5, HEP02.	4.2	3
220	Loss of myeloidâ€specific lamin A/C drives lung metastasis through Gfiâ€1 and C/EBPεâ€mediated granulocytic differentiation. Molecular Carcinogenesis, 2020, 59, 679-690.	1.3	3
221	Molecular markers of the EGFR pathway in erlotinib-treated patients with advanced pancreatic cancer (APC): Translational analyses of a randomized, cross-over AIO phase III trial Journal of Clinical Oncology, 2011, 29, 4047-4047.	0.8	3
222	Immune checkpoint inhibition (ICI) in combination with SBRT in patients with advanced pancreatic adenocarcinoma (aPDAC) Journal of Clinical Oncology, 2019, 37, 192-192.	0.8	3
223	Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma. Journal of Liver Cancer, 2020, 20, 1-16.	0.3	3
224	CD40 in hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2003, 15, 113-114.	0.8	2
225	Abstract A195: Tremelimimab activates CD4 and CD8+ T cells in patients with hepatocellular carcinoma. , 2016, , .		2
226	Phase I/II study of ISIS 183750 in combination with irinotecan for advanced solid tumors or colorectal cancer: Final results Journal of Clinical Oncology, 2015, 33, 639-639.	0.8	2
227	A pilot study of AMP-224—a PD-1 inhibitor—in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer Journal of Clinical Oncology, 2015, 33, TPS788-TPS788.	0.8	2
228	Representational difference analysis based identification and full-length sequencing of the B10-gene of the aldo-keto reductase family 1 clearly overexpressed in hepatocellular carcinoma. Journal of Hepatology, 2003, 38, 97-98.	1.8	1
229	215 A PHASE II OPEN LABEL TRIAL EVALUATING SAFETY AND EFFICACY OF A TELOMERASE PEPTIDE VACCINATION IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2010, 52, S92.	1.8	1
230	Immune studies in a mouse model of MET and CAT induced liver tumors. , 2014, 2, .		1
231	The ABC of adaptive immunity in liver cancer. Hepatology, 2018, 68, 777-779.	3.6	1
232	Cytokine-induced killer cells recruit myeloid derived suppressor cells in HCC, which can be targeted by a PDE5 inhibitor. Journal of Hepatology, 2018, 68, S95-S96.	1.8	1
233	Immune Therapies. Molecular and Translational Medicine, 2019, , 239-253.	0.4	1
234	Abstract 360: Senescent hepatocytes secrete CCL2 to accelerate liver cancer growth via accumulation of immunosuppressive myeloid cells. Cancer Research, 2015, 75, 360-360.	0.4	1

#	Article	IF	CITATIONS
235	A multicenter randomized phase II study of NPC-1C (N) in combination with gemcitabine (G) and nab-paclitaxel (A) versus G and A alone in patients with metastatic or locally advanced pancreatic cancer (PC) previously treated with folfirinox (F) Journal of Clinical Oncology, 2015, 33, TPS499-TPS499.	0.8	1
236	A pilot study of immune checkpoint inhibition (tremelimumab and/or MEDI4736) in combination with radiation therapy in patients with unresectable pancreatic cancer Journal of Clinical Oncology, 2016, 34, TPS470-TPS470.	0.8	1
237	Tumour-Associated Transcripts and EGFR Deletion Variants in Colorectal Cancer in Primary Tumour, Metastases and Circulating Tumour Cells. Analytical Cellular Pathology, 2008, 30, 463-471.	0.7	1
238	Correlation of hand-foot skin reaction (HFS) with treatment efficacy in pancreatic cancer (PC) patients (pts) treated with gemcitabine/capecitabine plus erlotinib: A subgroup analysis from the AIO-PK0104 randomized, cross-over phase III trial in advanced PC Journal of Clinical Oncology, 2012, 30, 4023-4023.	0.8	1
239	Abstract A132: Nonalcoholic fatty liver disease causes selective CD4+ lymphocytes loss and promotes hepatocarcinogenesis. , 2016, , .		1
240	Abstract 936: Single cell analysis reveals cancer stem cell heterogeneities in hepatocellular carcinoma. Cancer Research, 2017, 77, 936-936.	0.4	1
241	An open label phase 1b/2 trial of TRC105 and sorafenib in patient with advanced/metastatic hepatocellular carcinoma (HCC) (NCT01806064) Journal of Clinical Oncology, 2018, 36, 301-301.	0.8	1
242	Abstract A02: Gut microbiome controls growth of liver tumors. , 2018, , .		1
243	Cancer Vaccines. Current Protocols in Human Genetics, 1997, 14, Unit 13.8.	3.5	0
244	393 Impaired trail-dependent cytotoxicity of CD1C-positive dendritic cells in chronic hepatitis C virus infection. Journal of Hepatology, 2004, 40, 117.	1.8	0
245	[370] IMPAIRED DENDRITIC CELLS IN TUMORS OF PATIENTS WITH HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2007, 46, S144.	1.8	0
246	566 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ANALYSIS FOR THE DIAGNOSIS OF HCC. Journal of Hepatology, 2010, 52, S225.	1.8	0
247	590 QUALITATIVE ANALYSIS OF INTERNATIONAL GUIDELINES FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA BY THE AGREE INSTRUMENT (APPRAISAL OF GUIDELINES FOR RESEARCH AND)	Tj ET ®Qq1	1 00784314
248	Introductory message from the Editors. United European Gastroenterology Journal, 2013, 1, 6-6.	1.6	0
249	Message from the editors. United European Gastroenterology Journal, 2014, 2, 331-332.	1.6	0
250	Our experts highlight the most important research articles across the spectrum of topics relevant to the field of hepatic oncology. Hepatic Oncology, 2014, 1, 359-360.	4.2	0
251	2259 Tremelimumab - A monoclonal antibody against CTLA-4 - in combination with local tumor ablation (TACE or RFA) in patients with hepatocellular carcinoma (HCC). European Journal of Cancer, 2015, 51, S419.	1.3	0
252	Immune play: defending the liver. Hepatic Oncology, 2015, 2, 15-18.	4.2	0

#	Article	IF	CITATIONS
253	Future Therapy of Cholangiocarcinoma. Visceral Medicine, 2016, 32, 431-433.	0.5	Ο
254	Shall we blame CD4 T cells for everything?. Gut, 2017, 66, 763-764.	6.1	0
255	Gut Microbiome and Liver Cancer. Physiology in Health and Disease, 2021, , 199-255.	0.2	Ο
256	Evaluating the impact of hydroxychloroquine on mouse lymphocyte proliferation and cytokine production inÂvivo and in vitro. STAR Protocols, 2021, 2, 100517.	0.5	0
257	1874 Usefulness of aortic valve resistance in assessment of haemodynamic severity in aortic stenosis. European Heart Journal, 2003, 24, 359.	1.0	0
258	MHC-lg Dimeric Molecules. , 2005, , 227-238.		0
259	Comparative analysis of myeloid-derived suppressor cell (MDSC) subsets in patients with gastrointestinal (GI) malignancies Journal of Clinical Oncology, 2012, 30, 228-228.	0.8	0
260	Abstract 5412: CCR4+CCR6+Th17 cells suppress autologous CD8+ T cell responses in patients with hepatocellular carcinoma. , 2012, , .		0
261	Abstract B30: Cross-priming of CD8+ T cells is controlled by dipeptidyl peptidase 3 and thimet oligopeptidase 1 present in necrotic cells , 2013, , .		Ο
262	Effect of the addition of platinum to gemcitabine on outcome in patients with advanced pancreatic cancer who progress on gemcitabine: A comprehensive analysis of published trials Journal of Clinical Oncology, 2013, 31, 275-275.	0.8	0
263	Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104) Journal of Clinical Oncology, 2013, 31, 189-189.	0.8	0
264	Abstract 467: Bcl2A1 - an IFN-gamma dependent master switch for the function of CD11b+Gr-1high myeloid derived suppressor cells , 2013, , .		0
265	TRC105 for the treatment of hepatocellular carcinoma: Preclinical data and preliminary results from two clinical trials evaluating monotherapy and combination with sorafenib Journal of Clinical Oncology, 2014, 32, 211-211.	0.8	Ο
266	Disconnect between earlier presentation patterns and application of curative treatments in HCC Journal of Clinical Oncology, 2014, 32, 187-187.	0.8	0
267	In Reply. Deutsches Ärzteblatt International, 2014, 111, 464.	0.6	Ο
268	Curative treatments and survival benefit in elderly patients with hepatocellular carcinoma: A SEER population-based analysis Journal of Clinical Oncology, 2015, 33, 355-355.	0.8	0
269	A phase I/II study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2015, 33, 291-291.	0.8	Ο
270	A phase 1/2 study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2015, 33, 4083-4083.	0.8	0

#	Article	IF	CITATIONS
271	Racial/ethnic disparities in hepatocellular carcinoma treatment and survival: Are we making progress?. Journal of Clinical Oncology, 2015, 33, e17591-e17591.	0.8	0
272	Abstract 3166: The role of CD4 T cells in murine model of NASH-promoted HCC. , 2015, , .		0
273	Abstract 875: Risk factors for hepatocellular carcinoma (HCC) by race/ ethnicity in the United States. , 2015, , .		0
274	Abstract A04: Systemic agonistic anti-CD40 treatment of tumor bearing mice modulates hepatic myeloid suppressive cells and causes immune-mediated liver damage. , 2015, , .		0
275	Abstract B44: The role of CD4 T cells in murine model of NASH-promoted HCC. , 2015, , .		0
276	Abstract 2653: Tremelimimab plus tumor ablation for patients with hepatocellular carcinoma: Clinical results, immunomonitoring analysis of peripheral T cells and tumor biopsies. , 2016, , .		0
277	Abstract 3421: Epidemiology and survival in patients with extragastric signet ring carcinoma. , 2016, , .		0
278	Abstract 5015: Pretreatment carcinoembryonic antigen levels predict survival in patients with rectal adenocarcinoma. , 2016, , .		0
279	Immune Suppressor Mechanisms in HCC. , 2017, , 121-135.		0
280	Tremelimumab: A monoclonal antibody against CTLA-4—In combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC) Journal of Clinical Oncology, 2017, 35, 88-88.	0.8	0
281	Abstract 3057: Gut microbiome controls liver metastasis. , 2017, , .		0
282	Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer (BTC) Journal of Clinical Oncology, 2018, 36, 365-365.	0.8	0
283	Abstract 2549: Development of CAR T-cell therapy targeting glypican-3 in liver cancer. , 2018, , .		0
284	Abstract 4500: Mechanisms of tumor-associated myeloid cells in modulating host immune microenvironment and metastatic progression. , 2019, , .		0
285	Abstract 1526: Colitis promotes intrahepatic cholangiocarcinoma via gut microbiome dependent, CXCL1/CXCR2 mediated MDSC accumulation. , 2019, , .		0
286	Abstract CN07-02: Immunotoxins targeting GPC3 for liver cancer. , 2019, , .		0
287	Innate lymphoid cells at the crossroadsÂof innate and adaptive immunity. Hepatology, 2022, 76, 903-905.	3.6	0
288	Abstract 2311: Analysis of glypican 3-targeted chimeric antigen receptor T cells in hepatocellular carcinoma cell and mouse models. , 2019, , .		0